Companies can grow organically or through acquisitions. Drugmaker Jazz Pharmaceuticals (JAZZ) is taking both routes. Demand for the company’s flagship Xyrem narcolepsy treatment continues to be red hot. Sales jumped 36% and 42% in the first and second quarters of the year, respectively. Xyrem made up 65% of Jazz’s total revenue in 2013. The leukemia treatment Erwinaze is also doing well.